This is an investigator-initiated, proof-of-concept, randomised, double-blind,
placebo-controlled, single-centre phase II study aiming to evaluate the efficacy, safety and
tolerability of self-administered subcutaneous 120 µg dasiglucagon with an investigational
trial device (i.e. a multi-dose reusable pen) for the treatment of postprandial hypoglycaemia
after Roux-en-Y gastric bypass (RYGB) surgery. The study is divided into an in-patient and
out-patient part.
The primary aim of the study is to compare the effects of self-administered 120 µg
dasiglucagon versus placebo on continuous glucose monitoring (CGM)-assessed time spent in
hypoglycaemia in RYGB-operated individuals in an out-patient setting.